This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (22)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Immunotherapy  • Alert me on articles by topic

Lisa B. Travis, BS; Jeffrey M. Weinberg, MD; Nanette B. Silverberg, MD
From the St Luke's-Roosevelt Hospital Center, New York, NY.

Arch Dermatol. 2003;139:571-574.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORT OF CASES

CASE 1

A 23-year-old Hispanic woman with Fitzpatrick type IV skin presented with vitiligo vulgaris affecting 75% of her face, including complete depigmentation of the eyelids, chin, cheeks, and perioral skin. This had developed progressively over a 2-year period. As is the standard practice of our vitiligo clinic, thyroid function testing, blood cell counts, and vitamin B₁₂ levels were taken; all were within normal limits. Mometasone furoate ointment was applied twice daily for 3 months with no signs of follicular repigmentation either on visual examination or with the use of the Wood light.

CASE 2

A 24-year-old man with Fitzpatrick type II skin presented with a history of vitiligo vulgaris for 12 years. At the time of presentation, he had depigmentation of 60% of his body surface area, including the eyelids, chin, axillae, elbows, hips, knees, and back. Thyroid function findings, blood . . . [Full Text of this Article]

CASE 3

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT

RELATED LETTER

Lack of Efficacy of Tacrolimus in the Treatment of Vitiligo in the Absence of UV-B Exposure
Nima Ostovari, Thierry Passeron, Jean-Philippe Lacour, and Jean-Paul Ortonne
Arch Dermatol. 2006;142(2):252-253.
EXTRACT | FULL TEXT  

RELATED ARTICLE

A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the Treatment of Childhood Vitiligo
Veronica Lepe, Benjamin Moncada, Juan Pablo Castanedo-Cazares, Maria Bertha Torres-Alvarez, Carlos A. Ortiz, and Antonio B. Torres-Rubalcava
Arch Dermatol. 2003;139(5):581-585.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Focal Acne During Topical Tacrolimus Therapy for Vitiligo
Bakos and Bakos
Arch Dermatol 2007;143:1223-1224.
FULL TEXT  

Lack of Efficacy of Tacrolimus in the Treatment of Vitiligo in the Absence of UV-B Exposure.
Ostovari et al.
Arch Dermatol 2006;142:252-253.
FULL TEXT  

New Insights and New Therapies in Vitiligo
Grimes
JAMA 2005;293:730-735.
FULL TEXT